Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab and Chemotherapy in Localized Triple-negative Breast Cancer
NCT04331067Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, cabiralizumab in triple-negative breast cancer (TNBC), sponsored by Washington University School of Medicine. Started Nov 2020; status: terminated.
02
Drugs
nivolumabcabiralizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04331067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331067.